HBIO Harvard Bioscience, Inc. - Common Stock
NASDAQ · Life Sciences Tools & Services · Voir sur SEC EDGAR ↗ clôture Oct 2, 2026 10-K/10-Q Aoû 11, 2026HBIO Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
HBIO Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.
| Date ex-dividende | Division | Type |
|---|---|---|
| 16 mars 2026 | 1-for-10 | Inverse |
| 4 novembre 2013 | 1319-for-1000 | Avant |
À propos de Harvard Bioscience, Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.
Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.
History
Harvard Bioscience was founded in 1901 by Dr. William T. Porter of Harvard Medical School. He began manufacturing his own physiology teaching equipment in the basement of the Harvard Medical School. Dr. Porter went on to found the American Journal of Physiology and became one of the leading physiologists of his day.
The company invented the mechanical syringe pump in the 1950s and a computer-controlled dosing pump in the 1980s.
In the early 1980s, the company started using the name Harvard Bioscience; the name was not officially changed to Harvard Bioscience, Inc. until 2000. The company completed their initial public offering on December 7, 2000. The names Harvard Apparatus and Harvard Bioscience are used pursuant to a license agreement between Harvard University and Harvard Bioscience, Inc.
From 1996 to 2005 the company completed 17 business acquisitions, including the BTX division acquisition in 2003.
In 2007 the company sold most of its Capital Equipment Business, including its Genomic Solutions division and its Belgian subsidiary, Maia Scientific.
The company spun off Harvard Apparatus Regenerative Technology, Inc. (HART) in 2013 and Jeff Duchemin became CEO in August 2013.
In 2014 the company acquired Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI).
In 2015 the company acquired HEKA Electronik of Germany.
In 2016 the company divested AHN Biotechnologie GmbH, which it acquired in 2012.
In 2018 Harvard Bioscience acquired St. Paul, Minnesota-based Data Sciences International for $71 million and sold its Denville Scientific subsidiary to Thomas Scientific for $20 million.
James Green was named President and CEO in July 2019 and the company's performance declined during the latter half of his six-year tenure. In 2019, the company's gross revenue was $116 million, down from $120.7 million in 2018. The company ended the year with $55 million in loans, down from $62.4 million in loans at the end of 2018. Loans were through Cerberus Capital and were subsequently refinanced in 2020 with a syndicate led by Citizens Financial Group. In September 2019 the company announced a restructuring program, including closing their Connecticut operation, downsizing in the United Kingdom, and a reduction in force of over 10% of headcount. Several additional restructurings were implemented from 2020 to 2024.
For approximately nine months in 2019-2020 the company had an activist investor in its stock, Engine Capital.
In 2020, during the COVID-19 pandemic, Harvard Bioscience received $6.1 million in federally backed small business loans from PNC Bank as part of the Paycheck Protection Program. The company promptly repaid this loan after receiving scrutiny related to it.
In the of summer of 2025 the board of directors of Harvard Bioscience was reconstituted and a new CEO was appointed and in December 2025 the company successfully refinanced its debt, obtaining a $40 million credit facility with BroadOak Capital.
Products
Harvard Bioscience offers a wide array of products for life science research. Their product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology.
Finance
The revenue of the company grew from $11.5 million in 1997 to $108.2 million in 2010, a CAGR of 19%. The revenue of the company for fy 2013 reached 105.57 million with the profit margin of 0.12% and operation margin of -1.01%.
In the 25 years since Harvard Bioscience went public in 2000, there have been several intervals in which the company's value was grossly misunderstood by the market and its stock significantly undervalued, including, most recently, in 2019 and 2026.
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
| Métrique | Tendance sur 5 ans | HBIO | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -5.6moyenne 5 ans ≈-21.7 | ≈-21.7 | · | · | |
| P/S (TTM) | 0.4moyenne 5 ans ≈1.4 | ≈1.4 | · | · | |
| P/B (MRQ) | 5.1moyenne 5 ans ≈2.4 | ≈2.4 | · | · | |
| EV / EBITDA | -1.3moyenne 5 ans ≈51.1 | ≈51.1 | · | · | |
| Cours / FCF (TTM) | -33.9moyenne 5 ans ≈802.1 | ≈802.1 | · | · | |
| Cours / Flux de trésorerie (TTM) | 58.3moyenne 5 ans ≈83.3 | ≈83.3 | · | · | |
| EV / Revenue (VE / Chiffre d'affaires) | 0.7moyenne 5 ans ≈1.7 | ≈1.7 | · | · | |
| EV / FCF (VE / FCF) | 11.8moyenne 5 ans ≈900.4 | ≈900.4 | · | · | |
| Cours / Actif net tangible (MRQ) | 31.7 | · | · | · |
La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
| Métrique | Tendance sur 5 ans | HBIO | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Marge Brute (TTM) | 58.2%moyenne 5 ans ≈57.1% | ≈57.1% | · | · | |
| Marge d'exploitation (TTM) | -0.28%moyenne 5 ans ≈-13.1% | ≈-13.1% | -46.3% | Premier rang | |
| EBITDA Margin (Marge EBITDA) | -56.1%moyenne 5 ans ≈-13.1% | ≈-13.1% | -46.3% | Premier rang | |
| Marge avant impôts (TTM) | -12.0%moyenne 5 ans ≈-17.8% | ≈-17.8% | -90.8% | Premier rang | |
| Marge nette (TTM) | -11.9%moyenne 5 ans ≈-18.1% | ≈-18.1% | -89.7% | Premier rang | |
| ROA (TTM) | -13.3%moyenne 5 ans ≈-14.6% | ≈-14.6% | -42.4% | Faible | |
| ROE (TTM) | -89.9%moyenne 5 ans ≈-84.5% | ≈-84.5% | -78.9% | Faible | |
| ROIC | -96.8%moyenne 5 ans ≈-20.8% | ≈-20.8% | -83.1% | Faible |
Santé financière Dette, liquidité, solvabilité — solidité du bilan
| Métrique | Tendance sur 5 ans | HBIO | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Dette / Capitaux propres (MRQ) | 4.9moyenne 5 ans ≈1.0 | ≈1.0 | · | · | |
| Ratio de liquidité (MRQ) | 1.9moyenne 5 ans ≈1.9 | ≈1.9 | 2.5 | Faible liquidité | |
| Quick Ratio (Ratio de liquidité réduite) | 1.1moyenne 5 ans ≈0.9 | ≈0.9 | 0.9 | Faible liquidité | |
| Dette à long terme / Capitaux propres (MRQ) | 4.9moyenne 5 ans ≈0.8 | ≈0.8 | · | · |
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
| Métrique | Tendance sur 5 ans | HBIO | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Revenue YoY (Chiffre d'affaires YoY) | -8.1%moyenne 5 ans ≈-2.7% | ≈-2.7% | · | · | |
| Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans) | -8.6%moyenne 5 ans ≈-4.3% | ≈-4.3% | · | · | |
| Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans) | -3.2% | · | · | · |
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
| Métrique | Tendance sur 5 ans | HBIO | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Asset Turnover (Rotation des actifs) | 0.8moyenne 5 ans ≈0.8 | ≈0.8 | 0.4 | Premier rang | |
| Inventory Turnover (Rotation des stocks) | 1.7moyenne 5 ans ≈1.8 | ≈1.8 | · | · | |
| Receivables Turnover (Rotation des créances) | 5.6moyenne 5 ans ≈6.1 | ≈6.1 | 5.7 | Faible | |
| Revenue / Employee (Chiffre d'affaires annuel ÷ employés (effectif déclaré, yfinance). Dérivé — pas un concept SEC-XBRL stocké.) | ≈$273.9K | · | · | · |
valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
| Période | Rapport | EPS Actual | BPA est. | Surprise |
|---|---|---|---|---|
| 30 juin 2026 | Aoû 11, 2026 | $-0.14 | $-0.21 | 34.6% |
| 31 mars 2026 | Mai 12, 2026 | $-0.77 | $-0.63 | -21.8% |
| 31 décembre 2025 | $0.00 | $0.36 | -100.0% | |
| 30 septembre 2025 | $0.00 | $0.05 | -100.0% | |
| 30 juin 2025 | $-0.10 | $-0.10 | 2.0% | |
| 31 mars 2025 | $-0.10 | $-0.41 | 75.5% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $87M | $94M | $112M | $113M | $119M | $102M | $116M | $121M | $77M | $105M | $109M | $109M | |
| Cost of Revenue | $37M | $39M | $46M | $53M | $51M | $44M | $52M | $58M | $38M | $56M | $60M | $59M | |
| Gross Profit | $50M | $55M | $66M | $61M | $68M | $58M | $64M | $63M | $39M | $48M | $49M | $49M | |
| R&D Expense | $9M | $10M | $12M | $12M | $11M | $9M | $11M | $11M | $6M | $5M | $6M | $5M | |
| SG&A Expense | $18M | $21M | $23M | $24M | $24M | $24M | $23M | $21M | $18M | $21M | $20M | $17M | |
| Operating Expenses | $98M | $61M | $64M | $68M | $66M | $58M | $64M | $62M | $40M | $51M | $50M | $43M | |
| Operating Income | $-49M | $-6M | $2M | $-7M | $2M | $221.0K | $377.0K | $984.0K | $-635.0K | $-3M | $-2M | $7M | |
| Interest Expense | · | · | · | · | · | · | · | $5M | $713.0K | $639.0K | $846.0K | $990.0K | |
| Other Non-op | $-3M | $-325.0K | $-227.0K | $302.0K | $-666.0K | $-806.0K | $-469.0K | $-4M | $-739.0K | $-179.0K | $-1M | $-1M | |
| Pretax Income | $-57M | $-12M | $-3M | $-9M | $-140.0K | $-7M | $-6M | $-8M | $-3M | $-3M | $-4M | $4M | |
| Income Tax | $-686.0K | $740.0K | $859.0K | $337.0K | $148.0K | $518.0K | $-815.0K | $-4M | $-605.0K | $1M | $15M | $2M | |
| Net Income | $-57M | $-12M | $-3M | $-10M | $-288.0K | $-8M | $-5M | $-3M | $-865.0K | $-4M | $-19M | $2M | |
| EPS (Basic) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | $-0.01 | · | $-0.12 | $-0.08 | $-0.02 | $-0.13 | $-0.57 | $0.07 | |
| EPS (Diluted) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | · | · | $-0.12 | $-0.08 | $-0.02 | $-0.13 | $-0.57 | $0.07 | |
| Shares (Basic) | 44,391,000 | 43,538,000 | 42,420,000 | 41,413,000 | 40,343,000 | 38,640,000 | 37,813,580 | 36,453,126 | 34,753,325 | 34,211,521 | 33,592,775 | 32,170,683 | |
| Shares (Diluted) | 44,391,000 | 43,538,000 | 42,420,000 | 41,413,000 | 40,343,000 | 38,640,000 | 37,813,580 | 36,453,126 | 34,753,325 | 34,211,521 | 33,592,775 | 33,236,569 | |
| EBITDA | $-49M | $-6M | $2M | $-7M | $2M | $221.0K | $377.0K | $984.0K | $-101.0K | $-3M | $-2M | · |
Bilan
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9M | $4M | $4M | $5M | $8M | $8M | $8M | $8M | $6M | $6M | $7M | $14M | |
| Receivables | $16M | $15M | $16M | $17M | $22M | $18M | $21M | $21M | $13M | $16M | $18M | $16M | |
| Inventory | $21M | $23M | $25M | $26M | $28M | $22M | $22M | $25M | $17M | $20M | $22M | $21M | |
| Other Current Assets | $3M | $3M | $4M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | |
| Current Assets | $48M | $45M | $49M | $51M | $62M | $52M | $54M | $58M | $48M | $45M | $51M | $57M | |
| PP&E (Net) | $5M | $5M | $4M | $3M | $3M | $4M | $5M | $6M | $4M | $4M | $6M | $5M | |
| PP&E (Gross) | $23M | $21M | $18M | $18M | $18M | $21M | $20M | $23M | $19M | $19M | $22M | $20M | |
| Accum. Depreciation | $18M | $16M | $14M | $15M | $14M | $17M | $15M | $17M | $16M | $15M | $16M | $15M | |
| Goodwill | $10M | $56M | $57M | $56M | $58M | $59M | $57M | $57M | $36M | $38M | $40M | $40M | |
| Intangibles | $8M | $11M | $16M | $21M | $27M | $33M | $38M | $46M | $10M | $17M | $21M | $21M | |
| Other Non-current Assets | $3M | $3M | $6M | $8M | $5M | $1M | $2M | $2M | $324.0K | $128.0K | $152.0K | $380.0K | |
| Total Assets | $80M | $127M | $137M | $145M | $162M | $156M | $165M | $169M | $109M | $108M | $120M | $136M | |
| Accounts Payable | $4M | $5M | $6M | $6M | $5M | $6M | $5M | $7M | $4M | $6M | $9M | $6M | |
| Accrued Liabilities | · | · | · | · | · | · | $6M | $7M | $4M | $5M | $4M | $4M | |
| Current Liabilities | $22M | $55M | $27M | $23M | $25M | $21M | $25M | $25M | $14M | $15M | $19M | $18M | |
| Capital Leases | $7M | $6M | $5M | $5M | $6M | $7M | $8M | · | · | · | · | · | |
| Deferred Tax | $317.0K | $710.0K | $776.0K | $590.0K | $2M | $2M | $2M | $2M | $3M | $6M | $4M | $1M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $486.0K | $3M | $749.0K | $3M | · | · | · | · | |
| Total Liabilities | $66M | $63M | $64M | $73M | $79M | $80M | $83M | $86M | $28M | $36M | $42M | $40M | |
| Long-term Debt | $36M | $37M | $37M | $47M | $48M | $48M | $54M | $61M | $12M | $14M | $19M | $21M | |
| Total Debt | $36M | $37M | $37M | $47M | $49M | $48M | $50M | $59M | $9M | $11M | $16M | · | |
| Common Stock | $447.0K | $441.0K | $434.0K | $454.0K | $452.0K | $444.0K | $438.0K | $436.0K | $419.0K | $418.0K | $416.0K | $397.0K | |
| Retained Earnings | $-215M | $-158M | $-146M | $-142M | $-133M | $-132M | $-125M | $-120M | $-117M | $-116M | $-112M | $-93M | |
| Treasury Stock | · | · | · | · | $0 | $11M | · | · | · | · | · | · | |
| AOCI | $-12M | $-16M | $-14M | $-15M | $-10M | $-13M | $-13M | $-14M | $-11M | $-17M | $-12M | $-8M | |
| Stockholders' Equity | $14M | $63M | $73M | $72M | $83M | $77M | $82M | $83M | $81M | $72M | $78M | $95M | |
| Liabilities + Equity | $80M | $127M | $137M | $145M | $162M | $156M | $165M | $169M | $109M | $108M | $120M | $136M | |
| Shares Outstanding | 4,471,989 | 44,074,475 | 43,394,509 | 42,081,707 | 41,142,876 | 39,407,080 | 38,188,208 | 37,378,802 | 35,018,478 | 35,018,478 | 33,979,265 | 32,563,256 |
Flux de trésorerie
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $4M | $5M | $4M | $4M | $4M | $3M | $3M | $4M | $3M | $3M | $2M | |
| Deferred Tax | $-553.0K | $310.0K | $228.0K | $-498.0K | $-371.0K | $-143.0K | $-398.0K | $-4M | $-2M | $-279.0K | $15M | $1M | |
| Amort. of Intangibles | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $5M | $2M | $3M | $3M | $3M | |
| Restructuring | $200.0K | $800.0K | $391.0K | $2M | $1M | $2M | $1M | · | $0 | $-4.0K | $788.0K | $1M | |
| Operating Cash Flow | $7M | $1M | $14M | $1M | $1M | $9M | $8M | $3M | $1M | $5M | $705.0K | $4M | |
| CapEx | $1M | $3M | $2M | $2M | $1M | $1M | $1M | $986.0K | $890.0K | · | · | · | |
| Investing Cash Flow | $-2M | $-1M | $-2M | $-2M | $-1M | $-1M | $-229.0K | $-54M | $-917.0K | $-62.0K | $-8M | $-14M | |
| Debt Issued | $40M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $15M | $-6M | $-4M | $-3M | $-4M | $-67M | $-12M | $-20M | $-5M | $-9M | $-8M | · | |
| Stock Issued | · | · | · | · | · | · | · | $5M | $160.0K | $182.0K | $2M | $2M | |
| Net Stock Activity | · | · | · | · | · | · | · | $5M | $160.0K | $182.0K | $2M | · | |
| Financing Cash Flow | $-1M | $-131.0K | $-12M | $-3M | $-252.0K | $-8M | $-8M | $53M | $-2M | $-5M | $-540.0K | $-1M | |
| Net Change in Cash | $5M | $-175.0K | $-225.0K | $-3M | $-496.0K | $-18.0K | $162.0K | $2M | $137.0K | $-1M | $-7M | $-12M | |
| Taxes Paid | $-98.0K | $-159.0K | $207.0K | $534.0K | $577.0K | $416.0K | $374.0K | $98.0K | $13.0K | · | · | · | |
| Free Cash Flow | $5M | $-1M | $12M | $-438.0K | $67.0K | $8M | $7M | $2M | · | · | · | · | |
| Levered FCF | · | · | · | · | · | · | · | $-995.1K | · | · | · | · |
Rentabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.7% | 58.2% | 58.9% | 53.7% | 56.9% | 56.9% | 55.4% | 52.3% | 46.7% | 46.3% | 44.8% | · | |
| Operating Margin | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% | 0.22% | 0.32% | 0.81% | -0.10% | -2.9% | -1.6% | · | |
| Net Margin | -65.5% | -13.2% | -3.0% | -8.4% | -0.24% | -7.6% | -4.0% | -2.4% | -0.85% | -4.1% | -17.5% | · | |
| Pretax Margin | -66.3% | -12.4% | -2.3% | -8.1% | -0.12% | -7.1% | -4.7% | -6.6% | -2.1% | -2.9% | -3.3% | · | |
| EBITDA Margin | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% | 0.22% | 0.32% | 0.81% | -0.10% | -2.9% | -1.6% | · | |
| ROA | -54.9% | -9.4% | -2.4% | -6.2% | -0.18% | -4.9% | -2.8% | -2.1% | -0.80% | -3.8% | -14.9% | · | |
| ROE | -384.8% | -19.3% | -4.6% | -13.2% | -0.36% | -10.2% | -5.9% | -3.6% | -1.1% | -5.8% | -22.0% | · | |
| ROIC | -96.8% | -6.6% | 2.3% | -6.0% | 3.2% | 0.19% | 0.24% | 0.37% | -0.05% | -5.0% | -9.6% | · |
Liquidité et Solvabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 0.8 | 1.8 | 2.2 | 2.4 | 2.5 | 2.1 | 2.7 | 3.4 | 3.1 | 2.6 | · | |
| Quick Ratio | 1.1 | 0.3 | 0.8 | 0.9 | 1.2 | 1.2 | 1.1 | 1.4 | 1.6 | 1.5 | 1.3 | · | |
| Debt / Equity | 2.6 | 0.6 | 0.5 | 0.7 | 0.6 | 0.6 | 0.6 | 0.7 | 0.1 | 0.2 | 0.2 | · | |
| LT Debt / Equity | 2.6 | 0.0 | 0.4 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | 0.1 | 0.2 | 0.2 | · | |
| Interest Coverage | · | · | · | · | · | · | · | 0.2 | -0.1 | -4.7 | -2.0 | · |
Efficacité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.7 | 0.9 | 0.9 | 0.9 | 0.8 | · | |
| Inventory Turnover | 1.7 | 1.6 | 1.8 | 1.9 | 2.1 | 2.0 | 2.2 | 2.7 | 2.6 | 2.7 | 2.8 | · | |
| Receivables Turnover | 5.6 | 6.1 | 6.8 | 5.9 | 6.0 | 5.3 | 5.5 | 6.9 | 6.4 | 6.3 | 6.5 | · |
Par action
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.31 | $1.44 | $1.68 | $1.72 | $2.03 | $1.95 | $2.14 | $2.21 | $2.31 | $2.10 | $2.28 | · | |
| Revenue / Share | $1.95 | $2.16 | $2.65 | $2.74 | $2.95 | $2.64 | $3.07 | $3.31 | $2.93 | $3.06 | $3.23 | · | |
| Cash Flow / Share | $0.15 | $0.03 | $0.33 | $0.03 | $0.03 | $0.24 | $0.21 | $0.08 | $0.03 | $0.16 | $0.02 | · | |
| Cash / Share | $0.19 | $0.09 | $0.10 | $0.11 | $0.19 | $0.21 | $0.22 | $0.22 | $0.16 | $0.16 | $0.20 | · | |
| EPS (TTM) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | · | $-0.21 | $-0.12 | $-0.08 | $-0.02 | $-0.13 | $-0.57 | $0.07 |
Taux de croissance
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -8.1% | -16.1% | -0.96% | -4.7% | 16.5% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -8.6% | -7.5% | 3.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -3.2% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM)
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $87M | $94M | $112M | $113M | $119M | $102M | $116M | $121M | $77M | $105M | $109M | $109M | |
| Net Income TTM | $-57M | $-12M | $-3M | $-10M | $-288.0K | $-8M | $-5M | $-3M | $-865.0K | $-4M | $-19M | $2M | |
| Market Cap | $30M | $93M | $232M | $117M | $290M | $169M | $116M | $119M | $116M | $105M | $118M | · | |
| Enterprise Value | $57M | $126M | $265M | $159M | $331M | $209M | $158M | $169M | $119M | $111M | $128M | · | |
| P/E | -0.5 | -7.5 | -66.9 | -12.0 | · | -20.4 | -25.4 | -39.8 | -165.0 | -23.5 | -6.1 | 81.0 | |
| P/S | 0.3 | 1.0 | 2.1 | 1.0 | 2.4 | 1.7 | 1.0 | 1.0 | 1.5 | 1.0 | 1.1 | · | |
| P/B | 2.2 | 1.5 | 3.2 | 1.6 | 3.5 | 2.2 | 1.4 | 1.4 | 1.4 | 1.5 | 1.5 | · | |
| P / Cash Flow | 4.5 | 64.6 | 16.5 | 101.2 | 229.8 | 18.1 | 14.5 | 41.2 | 109.3 | 19.5 | 167.2 | · | |
| P / FCF | 5.5 | -77.2 | 19.0 | -266.1 | 4329.2 | 20.7 | 17.1 | 62.6 | · | · | · | · | |
| EV / EBITDA | -1.2 | -20.3 | 139.8 | -23.0 | 160.1 | 945.8 | 419.8 | 172.2 | -1176.3 | -37.0 | -74.5 | · | |
| EV / FCF | 10.5 | -104.8 | 21.6 | -363.4 | 4938.0 | 25.6 | 23.2 | 89.3 | · | · | · | · | |
| EV / Revenue | 0.7 | 1.3 | 2.4 | 1.4 | 2.8 | 2.0 | 1.4 | 1.4 | 1.5 | 1.1 | 1.2 | · | |
| Earnings Yield | -191.0% | -13.3% | -1.5% | -8.3% | · | -4.9% | -3.9% | -2.5% | -0.61% | -4.3% | -16.4% | 1.2% |
Compte de résultat
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23M | $21M | $24M | $21M | $20M | $22M | $25M | $22M | $23M | $25M | $28M | $25M | $29M | $30M | $28M | $27M | |
| Cost of Revenue | $10M | $9M | $10M | $9M | $9M | $10M | $11M | $9M | $10M | $10M | $12M | $11M | $12M | $12M | $13M | $15M | |
| Gross Profit | $13M | $12M | $14M | $12M | $12M | $12M | $14M | $13M | $13M | $15M | $16M | $15M | $17M | $18M | $16M | $12M | |
| R&D Expense | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| SG&A Expense | $5M | $5M | $4M | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $5M | $6M | $5M | $6M | $6M | $6M | |
| Operating Expenses | $14M | $13M | $12M | $12M | $12M | $62M | $14M | $15M | $15M | $17M | $16M | $16M | $16M | $17M | $16M | $16M | |
| Operating Income | $-978.0K | $-1M | $2M | $197.0K | $-819.0K | $-50M | $11.0K | $-2M | $-2M | $-2M | $282.0K | $-933.0K | $796.0K | $2M | $-457.0K | $-4M | |
| Other Non-op | $-125.0K | $-405.0K | $-1M | $-365.0K | $-434.0K | $-193.0K | $516.0K | $-518.0K | $-181.0K | $-142.0K | $-332.0K | $45.0K | $-372.0K | $432.0K | $465.0K | $-179.0K | |
| Pretax Income | $-3M | $-3M | $-3M | $-1M | $-2M | $-51M | $590.0K | $-4M | $-3M | $-4M | $-1M | $-562.0K | $-2M | $1M | $-892.0K | $-5M | |
| Income Tax | $14.0K | $117.0K | $-357.0K | $97.0K | $28.0K | $-454.0K | $572.0K | $311.0K | $-353.0K | $210.0K | $715.0K | $677.0K | $-1M | $585.0K | $774.0K | $-1M | |
| Net Income | $-3M | $-3M | $-3M | $-1M | $-2M | $-50M | $18.0K | $-5M | $-3M | $-5M | $-2M | $-1M | $-980.0K | $622.0K | $-2M | $-3M | |
| EPS (Basic) | $-0.64 | $-0.77 | $-0.06 | $-0.03 | $-0.52 | $-11.42 | $0.01 | $-0.11 | $-0.07 | $-0.11 | $-0.04 | $-0.03 | $-0.02 | $0.01 | $-0.04 | $-0.08 | |
| EPS (Diluted) | $-0.64 | $-0.77 | $-0.06 | $-0.03 | $-0.52 | $-11.42 | $0.01 | $-0.11 | $-0.07 | $-0.11 | $-0.04 | $-0.03 | $-0.02 | $0.01 | $-0.04 | $-0.08 | |
| Shares (Basic) | 4,526,000 | 4,473,000 | · | 44,556,000 | 4,430,000 | 4,410,000 | · | 43,614,000 | 43,486,000 | 43,402,000 | · | 42,688,000 | 42,354,000 | 42,119,000 | · | 41,637,000 | |
| Shares (Diluted) | 4,526,000 | 4,473,000 | · | 44,556,000 | 4,430,000 | 4,410,000 | · | 43,614,000 | 43,486,000 | 43,402,000 | · | 42,688,000 | 42,354,000 | 42,783,000 | · | 41,637,000 | |
| EBITDA | $-978.0K | $-1M | · | $197.0K | $-819.0K | $-50M | · | $-2M | $-2M | $-2M | · | $-933.0K | $796.0K | $2M | · | $-4M |
Bilan
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7M | $7M | $9M | $7M | $7M | $6M | $4M | $5M | $4M | $4M | $4M | $5M | $4M | $4M | $5M | $5M | |
| Receivables | $14M | $15M | $16M | $12M | $12M | $13M | $15M | $13M | $12M | $15M | $16M | $15M | $17M | $18M | $17M | $15M | |
| Inventory | $22M | $22M | $21M | $22M | $22M | $23M | $23M | $26M | $25M | $24M | $25M | $26M | $26M | $27M | $26M | $26M | |
| Other Current Assets | $3M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $4M | $4M | $4M | $5M | $4M | $3M | $6M | |
| Current Assets | $46M | $47M | $48M | $44M | $45M | $45M | $45M | $47M | $46M | $48M | $49M | $50M | $53M | $52M | $51M | $52M | |
| PP&E (Net) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $3M | $3M | $3M | $3M | $4M | |
| PP&E (Gross) | · | · | $23M | · | · | · | $21M | · | · | · | $18M | · | · | · | $18M | · | |
| Accum. Depreciation | · | · | $18M | · | · | · | $16M | · | · | · | $14M | · | · | · | $15M | · | |
| Goodwill | $9M | $9M | $10M | $10M | $10M | $9M | $56M | $57M | $57M | $57M | $57M | $56M | $57M | $57M | $56M | $55M | |
| Intangibles | $6M | $7M | $8M | $8M | $9M | $10M | $11M | $12M | $13M | $15M | $16M | $17M | $18M | $20M | $21M | $22M | |
| Other Non-current Assets | $3M | $3M | $3M | $4M | $4M | $4M | $3M | $3M | $3M | $5M | $6M | $8M | $6M | $8M | $8M | $8M | |
| Total Assets | $76M | $78M | $80M | $78M | $80M | $80M | $127M | $131M | $129M | $133M | $137M | $140M | $143M | $146M | $145M | $147M | |
| Accounts Payable | $6M | $5M | $4M | $5M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | |
| Current Liabilities | $25M | $24M | $22M | $54M | $55M | $56M | $55M | $23M | $23M | $26M | $27M | $24M | $23M | $23M | $23M | $21M | |
| Capital Leases | $6M | $6M | $7M | $7M | $7M | $7M | $6M | $7M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $6M | |
| Deferred Tax | $311.0K | $313.0K | $317.0K | $733.0K | $734.0K | $717.0K | $710.0K | $707.0K | $764.0K | $772.0K | $776.0K | $661.0K | $667.0K | $546.0K | $590.0K | $1M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $892.0K | $1M | $1M | $1M | $420.0K | |
| Total Liabilities | $69M | $68M | $66M | $64M | $64M | $65M | $63M | $66M | $62M | $64M | $64M | $65M | $68M | $71M | $73M | $75M | |
| Long-term Debt | $37M | $36M | $36M | $34M | $35M | $36M | $37M | $38M | $36M | $36M | $37M | $39M | $41M | $44M | $47M | $49M | |
| Total Debt | $37M | $36M | · | · | · | · | · | $38M | $36M | $36M | · | $39M | $42M | $44M | · | $50M | |
| Common Stock | $447.0K | $447.0K | $447.0K | $446.0K | $445.0K | $442.0K | $441.0K | $436.0K | $436.0K | $434.0K | $434.0K | $457.0K | $457.0K | $455.0K | $454.0K | $453.0K | |
| Retained Earnings | $-221M | $-218M | $-215M | $-212M | $-211M | $-208M | $-158M | $-158M | $-153M | $-150M | $-146M | $-144M | $-143M | $-142M | $-142M | $-141M | |
| AOCI | $-12M | $-12M | $-12M | $-12M | $-12M | $-14M | $-16M | $-13M | $-15M | $-15M | $-14M | $-15M | $-14M | $-15M | $-15M | $-16M | |
| Stockholders' Equity | $7M | $10M | $14M | $14M | $16M | $15M | $63M | $65M | $67M | $69M | $73M | $74M | $75M | $74M | $72M | $72M | |
| Liabilities + Equity | $76M | $78M | $80M | $78M | $80M | $80M | $127M | $131M | $129M | $133M | $137M | $140M | $143M | $146M | $145M | $147M | |
| Shares Outstanding | 4,552,305 | 4,510,182 | 44,719,894 | 44,579,665 | 44,531,198 | 44,213,746 | 44,074,475 | 43,616,621 | 43,610,883 | 43,421,251 | 43,394,509 | 42,688,246 | 42,688,246 | 42,190,043 | 42,081,707 | 41,657,688 |
Flux de trésorerie
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $380.0K | $257.0K | $459.0K | $324.0K | $472.0K | $600.0K | $961.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Amort. of Intangibles | $820.0K | $820.0K | $850.0K | $855.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | |
| Restructuring | $318.0K | $235.0K | $29.0K | $48.0K | $30.0K | $93.0K | $225.0K | $179.0K | $396.0K | $0 | · | · | · | · | $485.0K | $1M | |
| Operating Cash Flow | $325.0K | $-662.0K | $-96.0K | $1M | $3M | $3M | $2M | $-842.0K | $-846.0K | $1M | $4M | $4M | $4M | $2M | $3M | $649.0K | |
| CapEx | $688.0K | $426.0K | $449.0K | $207.0K | $89.0K | $513.0K | $301.0K | $880.0K | $818.0K | $645.0K | $830.0K | $217.0K | $517.0K | $224.0K | $235.0K | $442.0K | |
| Investing Cash Flow | $-916.0K | $-620.0K | $-599.0K | $-348.0K | $-233.0K | $-683.0K | $-466.0K | $-1M | $458.0K | $-225.0K | $-1M | $-401.0K | $-625.0K | $288.0K | $-235.0K | $-442.0K | |
| Net Debt Issued | · | $0 | · | · | · | $-1M | · | · | · | $-3M | · | · | · | $-2M | · | · | |
| Financing Cash Flow | $-38.0K | $-9.0K | $2M | $-1M | $-1M | $-1M | $-1M | $2M | $177.0K | $-1M | $-4M | $-3M | $-2M | $-3M | $-3M | $377.0K | |
| Net Change in Cash | $-595.0K | $-2M | $2M | $-625.0K | $2M | $1M | $-461.0K | $521.0K | $-207.0K | $-28.0K | $-1M | $1M | $535.0K | $-719.0K | $-636.0K | $885.0K | |
| Taxes Paid | $-164.0K | $-5.0K | $-144.0K | $-2.0K | $46.0K | $2.0K | $-474.0K | $184.0K | $105.0K | $26.0K | $39.0K | $53.0K | $249.0K | $-134.0K | $41.0K | $141.0K | |
| Free Cash Flow | · | $-1M | · | · | · | $2M | · | · | · | $758.0K | · | · | · | $2M | · | · |
Rentabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.6% | 59.0% | · | 58.4% | 56.4% | 56.0% | · | 58.1% | 57.2% | 60.3% | · | 58.1% | 58.0% | 61.2% | · | 45.2% | |
| Operating Margin | -4.3% | -5.7% | · | 0.96% | -4.0% | -228.1% | · | -8.5% | -9.0% | -9.3% | · | -3.7% | 2.8% | 5.8% | · | -14.0% | |
| Net Margin | -12.8% | -16.5% | · | -6.0% | -11.2% | -231.2% | · | -21.9% | -12.7% | -19.1% | · | -4.9% | -3.4% | 2.1% | · | -12.7% | |
| Pretax Margin | -12.7% | -15.9% | · | -5.5% | -11.0% | -233.3% | · | -20.4% | -14.2% | -18.3% | · | -2.2% | -7.3% | 4.0% | · | -17.4% | |
| EBITDA Margin | -4.3% | -5.7% | · | 0.96% | -4.0% | -228.1% | · | -8.5% | -9.0% | -9.3% | · | -3.7% | 2.8% | 5.8% | · | -14.0% | |
| ROA | -3.7% | -4.3% | · | -1.2% | -2.2% | -47.3% | · | -3.5% | -2.1% | -3.4% | · | -0.86% | -0.66% | 0.41% | · | -2.3% | |
| ROE | -25.1% | -27.5% | · | -3.1% | -5.5% | -120.4% | · | -6.9% | -4.1% | -6.6% | · | -1.7% | -1.3% | 0.83% | · | -4.6% | |
| ROIC | -2.2% | -2.6% | · | 1.5% | -5.3% | -331.8% | · | -1.9% | -1.8% | -2.3% | · | -1.8% | 0.32% | 0.76% | · | -2.2% |
Liquidité et Solvabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.0 | · | 0.8 | 0.8 | 0.8 | · | 2.1 | 2.1 | 1.9 | · | 2.1 | 2.3 | 2.3 | · | 2.4 | |
| Quick Ratio | 0.8 | 0.9 | · | 0.3 | 0.4 | 0.3 | · | 0.8 | 0.7 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 0.9 | |
| Debt / Equity | 4.9 | 3.6 | · | · | · | · | · | 0.6 | 0.5 | 0.5 | · | 0.5 | 0.6 | 0.6 | · | 0.7 | |
| LT Debt / Equity | 4.9 | 3.6 | · | · | · | · | · | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.6 | · | 0.6 |
Efficacité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.6 | |
| Receivables Turnover | 1.7 | 1.5 | · | 1.7 | 1.7 | 1.5 | · | 1.6 | 1.6 | 1.5 | · | 1.7 | 1.7 | 1.6 | · | 1.6 |
Par action
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.63 | $2.23 | · | $0.32 | $0.35 | $0.34 | · | $1.50 | $1.54 | $1.58 | · | $1.74 | $1.77 | $1.76 | · | $1.73 | |
| Revenue / Share | $5.02 | $4.64 | · | $0.46 | $0.46 | $0.49 | · | $0.50 | $0.53 | $0.56 | · | $0.59 | $0.68 | $0.70 | · | $0.65 | |
| Cash Flow / Share | · | $-0.15 | · | · | · | $0.07 | · | · | · | $0.03 | · | · | · | $0.04 | · | · | |
| Cash / Share | $1.43 | $1.57 | · | $0.15 | $0.17 | $0.13 | · | $0.10 | $0.09 | $0.10 | · | $0.13 | $0.10 | $0.09 | · | $0.12 | |
| EPS (TTM) | $-1.50 | $-1.38 | · | $-11.96 | $-12.04 | $-11.59 | · | $-0.33 | $-0.25 | $-0.20 | · | $-0.08 | $-0.13 | $-0.05 | · | · |
Valorisation (TTM)
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $86M | · | $87M | $89M | $91M | · | $98M | $101M | $107M | · | $113M | $114M | $115M | · | $118M | |
| Net Income TTM | $-10M | $-10M | · | $-54M | $-57M | $-58M | · | $-14M | $-11M | $-9M | · | $-3M | $-5M | $-2M | · | $-7M | |
| Market Cap | $28M | $22M | · | $20M | $20M | $25M | · | $117M | $124M | $184M | · | $184M | $234M | $177M | · | $107M | |
| Enterprise Value | $58M | $51M | · | · | · | · | · | $151M | $156M | $216M | · | $217M | $272M | $218M | · | $151M | |
| P/E | -4.1 | -3.5 | · | -0.0 | -0.0 | -0.0 | · | -8.2 | -11.4 | -21.2 | · | -53.8 | -42.2 | -84.0 | · | · | |
| P/S | 0.3 | 0.3 | · | 0.2 | 0.2 | 0.3 | · | 1.2 | 1.2 | 1.7 | · | 1.6 | 2.1 | 1.5 | · | 0.9 | |
| P/B | 3.8 | 2.2 | · | 1.4 | 1.2 | 1.7 | · | 1.8 | 1.8 | 2.7 | · | 2.5 | 3.1 | 2.4 | · | 1.5 | |
| P / Tangible Book | · | · | · | · | · | · | · | · | · | · | · | 189.4 | 897.9 | · | · | · | |
| P / Cash Flow | · | -33.2 | · | · | · | 8.4 | · | · | · | 131.2 | · | · | · | 97.8 | · | · | |
| EV / Revenue | 0.7 | 0.6 | · | · | · | · | · | 1.5 | 1.5 | 2.0 | · | 1.9 | 2.4 | 1.9 | · | 1.3 | |
| Earnings Yield | -24.4% | -28.3% | · | -2718.2% | -2736.4% | -2033.3% | · | -12.3% | -8.8% | -4.7% | · | -1.9% | -2.4% | -1.2% | · | · |
Période la plus récente à gauche · valeurs nulles affichées comme ·
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenu | $87M | $94M | $112M | $113M | $119M |
| Marge Brute % | 57.7% | 58.2% | 58.9% | 53.7% | 56.9% |
| Marge d'exploitation % | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% |
| Résultat net | $-57M | $-12M | $-3M | $-10M | $-288.0K |
| BPA dilué | $-1.28 | $-0.28 | $-0.08 | $-0.23 | · |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dette / Capitaux propres | 2.6 | 0.6 | 0.5 | 0.7 | 0.6 |
| Ratio de liquidité | 2.2 | 0.8 | 1.8 | 2.2 | 2.4 |
| Ratio de liquidité réduite | 1.1 | 0.3 | 0.8 | 0.9 | 1.2 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $5M | $-1M | $12M | $-438.0K | $67.0K |
Détenteurs institutionnels (13F) 8 déclarants · $5.7M total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 0 (0 vs T. préc.) | 0 (-57 vs T. préc.) | 2 (+2 vs T. préc.) | 0 (-3 vs T. préc.) | +90K |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| AMH Equity Ltd | $1 774 844 | 4 047 535 | 31,32% | Actions |
| VANGUARD GROUP INC | $1 286 671 | 1 923 275 | 22,71% | Actions |
| Meros Investment Management, LP | $1 125 401 | 182 992 | 19,86% | Actions |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $879 954 | 143 082 | 15,53% | Actions |
| TWO SIGMA ADVISERS, LP | $587 578 | 878 556 | 10,37% | Actions |
| Point72 Asia (Singapore) Pte. Ltd. | $6 445 | 14 697 | 0,11% | Actions |
| WOLVERINE TRADING, LLC | $5 102 | 11 600 | 0,09% | Option d'achat |
| Financial Connections Group, Inc. | $0 | 30 | 0,00% | Actions |
Activistes et détenteurs de 5%+ 5 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| BroadOak Income Fund, L.P., BroadOak Fund VI, L.P., BroadOak Capital Partners, LLC, William Snider | 23 mars 2026 | 15,97% | Dépôt initial | · | SEC |
| ENGINE CAPITAL, L.P., ENGINE JET CAPITAL, L.P., ENGINE CAPITAL MANAGEMENT, LP, ENGINE CAPITAL MANAGEMENT GP, LLC, ENGINE INVESTMENTS, LLC, ARNAUD AJDLER ×5 dépôts | 22 juin 2020 | · | Dépôt initial | · | SEC |
| HSO Limited Partnership Skystone Advisors LLC Kerry Nelson ×2 dépôts | 20 mai 2008 | · | Dépôt initial | · | SEC |
| 14 décembre 2007 | · | Dépôt initial | · | SEC | |
| Personne déclarante non divulguée | 29 juillet 2002 | · | Dépôt initial | Fusions et acquisitions / vente | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Initiés de la société 34 initiés · 14 dirigeants · 18 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| John D Duke | Chief Executive Officer | 20 mars 2026 A | 180 000 | 1 | 0 | $25 050 |
| Jeffrey Duchemin | Chief Executive Officer | 7 juillet 2019 D | 464 528 | 0 | 0 | $0 |
| Mark T Frost | Chief Financial Officer | 20 mars 2026 A | 47 500 | 1 | 0 | $25 000 |
| Jennifer Cote | Chief Financial Officer | 19 mars 2025 F | 159 019 | 0 | 0 | $0 |
| Michael A. Rossi | Chief Financial Officer | 29 décembre 2022 F | 260 540 | 0 | 0 | $0 |
| Kamalam Unninayar | Chief Financial Officer | 7 mars 2019 A | 73 858 | 0 | 0 | $0 |
| Bryce Anthony Chicoyne | Chief Financial Officer | 1 mai 2007 A | · | 0 | 0 | $0 |
| Mark A Norige | President, Harvard Apparatus | 1 mai 2007 A | · | 0 | 0 | $0 |
| David L Strack | President of Subsidiary | 25 mai 2005 A | · | 0 | 0 | $0 |
| Kenneth Fletcher Olson | Chief Operating Officer | 29 décembre 2021 F | 155 595 | 0 | 0 | $0 |
| Yash Singh | Executive Vice President | 31 octobre 2019 A | 39 286 | 0 | 0 | $0 |
| Yong Sun | VP - Commercial Operations | 1 janvier 2019 F | 242 805 | 0 | 0 | $0 |
| Yoav Sibony | VP - Global Sales | 3 août 2015 A | 21 582 | 0 | 0 | $0 |
| Paul Bailey | VP, Finance & Admin. | 25 mai 2005 A | · | 0 | 0 | $0 |
| Seth Benjamin Benson | Administrateur | 9 juin 2026 A | 27 556 | 0 | 0 | $0 |
| Katherine A. Eade | Administrateur | 9 juin 2026 A | 58 669 | 0 | 0 | $0 |
| Robert E. Gagnon | Administrateur | 9 juin 2026 A | 27 556 | 0 | 0 | $0 |
| William Snider | Administrateur | 9 juin 2026 A | 48 556 | 2 | 0 | $103 604 |
| Stephen J Denelsky | Administrateur | 9 juin 2026 A | 37 556 | 1 | 0 | $48 700 |
| James W Green | Administrateur | 15 août 2025 D | 2 452 566 | 0 | 0 | $0 |
| Thomas W Loewald | Administrateur | 21 mai 2024 A | 295 311 | 0 | 0 | $0 |
| Bertrand Loy | Administrateur | 21 mai 2024 A | 56 575 | 0 | 0 | $0 |
| Alan I Edrick | Administrateur | 21 mai 2024 A | 273 911 | 0 | 0 | $0 |
| John F Kennedy | Administrateur | 23 mars 2021 G | 323 344 | 0 | 0 | $0 |
| Susan M. Steele | Administrateur | 4 janvier 2021 A | 49 400 | 0 | 0 | $0 |
| George Uveges | Administrateur | 12 mars 2018 M | 142 685 | 0 | 0 | $0 |
| Earl R Lewis | Administrateur | 2 janvier 2018 A | 477 050 | 0 | 0 | $0 |
| David Green | Administrateur | 7 février 2017 S | 925 571 | 0 | 0 | $0 |
| Neal J Harte | Administrateur | 25 mai 2016 M | 106 399 | 0 | 0 | $0 |
| Robert A Dishman | Administrateur | 28 avril 2015 A | 51 055 | 0 | 0 | $0 |
| Chane Graziano | Détenteur de 10% | 7 novembre 2013 G | 3 005 150 | 0 | 0 | $0 |
| HSO LIMITED PARTNERSHIP | Détenteur de 10% | 16 mai 2008 S | 2 757 257 | 0 | 0 | $0 |
| Thomas Mcnaughton | · | 1 novembre 2013 J | 171 613 | 0 | 0 | $0 |
| Susan M Luscinski | · | 1 novembre 2013 J | 469 720 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Détention d'ETF Détenu par 2 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
HBIO Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
Objectif de cours à 12 mois
1 analystes · 2026-10-04Objectif moyen $7.50 -10,1%
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.